MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/24
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesGlobeNewsWire • 11/04/24
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 11/01/24
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024GlobeNewsWire • 10/31/24
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 10/31/24
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 09/18/24
Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the BoardGlobeNewsWire • 08/14/24
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/07/24
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development UpdateGlobeNewsWire • 08/07/24
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024GlobeNewsWire • 07/30/24
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 07/16/24